Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

被引：0
|
作者：
O. Katopodis
J. Souglakos
E. Stathopoulos
A. Christopoulou
E. Kontopodis
A. Kotsakis
K. Kalbakis
N. Kentepozidis
A. Polyzos
D. Hatzidaki
V. Georgoulias
机构：
[1] Hellenic Oncology Research Group (HORG),
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Gemcitabine; Oxaliplatin; Erlotinib; Phase II trial; Pancreas;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：333 / 340
页数：7
相关论文
共 50 条
  • [1] Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Katopodis, O.
    Souglakos, J.
    Stathopoulos, E.
    Christopoulou, A.
    Kontopodis, E.
    Kotsakis, A.
    Kalbakis, K.
    Kentepozidis, N.
    Polyzos, A.
    Hatzidaki, D.
    Georgoulias, V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 333 - 340
  • [2] Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: A Multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Kalykaki, Antonia
    Papakotoulas, Pavlos
    Tsousis, Sofoklis
    Boukovinas, Ioannis
    Kalbakis, Kostas
    Vamvakas, Lambros
    Kotsakis, Athanasios
    Vardakis, Nikolaos
    Papadopoulou, Persefoni
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    ANTICANCER RESEARCH, 2008, 28 (1B) : 495 - 500
  • [3] Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    Alberts, SR
    Townley, PM
    Goldberg, RM
    Cha, SS
    Sargent, DJ
    Moore, DF
    Krook, JE
    Pitot, HC
    Fitch, TR
    Wiesenfeld, M
    Mailliard, JA
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 580 - 585
  • [4] Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Boukovinas, Ioannis
    Androulakis, Nikolaos
    Kentepozidis, Nikolaos
    Polyzos, Aris
    Papakotoulas, Pavlos
    Ziras, Nikolaos
    Kotsakis, Athanasios
    Vardakis, Nikolaos
    Karampeazis, Athanasios
    Markos, Vassilis
    Kostakopoulos, Athanasios
    Constantinides, Constantine A.
    Samonis, George
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 351 - 356
  • [5] Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Ioannis Boukovinas
    Nikolaos Androulakis
    Nikolaos Kentepozidis
    Aris Polyzos
    Pavlos Papakotoulas
    Nikolaos Ziras
    Athanasios Kotsakis
    Nikolaos Vardakis
    Athanasios Karampeazis
    Vassilis Markos
    Athanasios Kostakopoulos
    Constantine A. Constantinides
    George Samonis
    Dimitris Mavroudis
    Vassilis Georgoulias
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 351 - 356
  • [6] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Kyung Hee Lee
    Min Kyoung Kim
    Yeol Hong Kim
    Baek Yeol Ryoo
    Ho Yeong Lim
    Hong Suk Song
    Hoon Kyo Kim
    Myung Ah Lee
    Seock Ah Im
    Heung Moon Chang
    Jae Yong Cho
    Dae Young Zang
    Bong Seog Kim
    Jun Suk Kim
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 317 - 325
  • [7] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Lee, Kyung Hee
    Kim, Min Kyoung
    Kim, Yeol Hong
    Ryoo, Baek Yeol
    Lim, Ho Yeong
    Song, Hong Suk
    Kim, Hoon Kyo
    Lee, Myung Ah
    Im, Seock Ah
    Chang, Heung Moon
    Cho, Jae Yong
    Zang, Dae Young
    Kim, Bong Seog
    Kim, Jun Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 317 - 325
  • [8] Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group
    Xiros, N
    Papacostas, P
    Economopoulos, T
    Samelis, G
    Efstathiou, E
    Kastritis, E
    Kalofonos, H
    Onyenatum, A
    Skarlos, D
    Bamias, A
    Gogas, H
    Bafaloukos, D
    Samantas, E
    Kosmidis, P
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 773 - 779
  • [9] Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study
    Alberts, SR
    Townley, PM
    Goldberg, RM
    Cha, SS
    Moore, DF
    Krook, JE
    Pitot, HC
    Fitch, TR
    Wiesenfeld, M
    Mailliard, JA
    Sargent, DJ
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 553 - 557
  • [10] Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer
    Merchan, Jaime R.
    Ferrell, Annaporna
    Macintyre, Jessica
    Ciombor, Kristen K.
    Levi, Joe
    Ribeiro, Afonso
    Sleeman, Danny
    Flores, Aurea
    Lopes, Gilberto
    Rocha-Lima, Caio M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (05): : 446 - 450
12345